| Ion Channels as Therapeutic Targets: A Drug Discovery Perspective SK Bagal, AD Brown, PJ Cox, K Omoto, RM Owen, DC Pryde, B Sidders, ... Journal of Medicinal Chemistry, 2012 | 344 | 2012 |
| A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis SL Kendall, M Withers, CN Soffair, NJ Moreland, S Gurcha, B Sidders, ... Molecular microbiology 65 (3), 684-699, 2007 | 270 | 2007 |
| Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon N Shimono, L Morici, N Casali, S Cantrell, B Sidders, S Ehrt, LW Riley Proceedings of the national academy of sciences 100 (26), 15918-15923, 2003 | 269 | 2003 |
| HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain F Denk, W Huang, B Sidders, A Bithell, M Crow, J Grist, S Sharma, ... Pain® 154 (9), 1668-1679, 2013 | 162 | 2013 |
| Causal reasoning on biological networks: interpreting transcriptional changes L Chindelevitch, D Ziemek, A Enayetallah, R Randhawa, B Sidders, ... Bioinformatics 28 (8), 1114-1121, 2012 | 154 | 2012 |
| Screening of Highly Expressed Mycobacterial Genes Identifies Rv3615c as a Useful Differential Diagnostic Antigen for the Mycobacterium tuberculosis Complex B Sidders, C Pirson, PJ Hogarth, RG Hewinson, NG Stoker, ... Infection and immunity 76 (9), 3932-3939, 2008 | 140 | 2008 |
| 5′‐Adenosinephosphosulphate reductase (CysH) protects Mycobacterium tuberculosis against free radicals during chronic infection phase in mice RH Senaratne, AD De Silva, SJ Williams, JD Mougous, JR Reader, ... Molecular microbiology 59 (6), 1744-1753, 2006 | 128 | 2006 |
| Mycobacterium tuberculosis strains disrupted in mce3 and mce4 operons are attenuated in mice RH Senaratne, B Sidders, P Sequeira, G Saunders, K Dunphy, ... Journal of medical microbiology 57 (2), 164-170, 2008 | 125 | 2008 |
| Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens E Goncalves, A Segura-Cabrera, C Pacini, G Picco, F Behan, P Jaaks, ... bioRxiv, 2020 | 88 | 2020 |
| Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens E Goncalves, A Segura-Cabrera, C Pacini, G Picco, F Behan, P Jaaks, ... bioRxiv, 2020 | 88 | 2020 |
| PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity LS Carnevalli, C Sinclair, MA Taylor, PM Gutierrez, S Langdon, ... Journal for immunotherapy of cancer 6 (1), 158, 2018 | 86 | 2018 |
| Genes contributing to pain sensitivity in the normal population: an exome sequencing study FMK Williams, S Scollen, D Cao, Y Memari, CL Hyde, B Zhang, B Sidders, ... PLoS genetics 8 (12), e1003095, 2012 | 74 | 2012 |
| Adenosine signalling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response B Sidders, P Zhang, K Goodwin, G O'Connor, DL Russell, A Borodovsky, ... Clinical Cancer Research, 2020 | 73 | 2020 |
| Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome … C Laxton, K Brady, S Moschos, P Turnpenny, J Rawal, DC Pryde, ... Antimicrobial agents and chemotherapy 55 (7), 3105-3114, 2011 | 68 | 2011 |
| Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer A Gogleva, D Polychronopoulos, M Pfeifer, V Poroshin, M Ughetto, ... Nature communications 13 (1), 1667, 2022 | 67 | 2022 |
| Interpreting transcriptional changes using causal graphs: new methods and their practical utility on public networks CT Fakhry, P Choudhary, A Gutteridge, B Sidders, P Chen, D Ziemek, ... BMC bioinformatics 17, 1-15, 2016 | 57 | 2016 |
| Network-based drug discovery: coupling network pharmacology with phenotypic screening for neuronal excitability B Sidders, A Karlsson, L Kitching, R Torella, P Karila, A Phelan Journal of molecular biology 430 (18), 3005-3015, 2018 | 51 | 2018 |
| The pain interactome: connecting pain-specific protein interactions DG Jamieson, A Moss, M Kennedy, S Jones, G Nenadic, DL Robertson, ... PAIN® 155 (11), 2243-2252, 2014 | 47 | 2014 |
| Phase ia/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors EA Lim, JC Bendell, GS Falchook, TM Bauer, CG Drake, JH Choe, ... Clinical Cancer Research 28 (22), 4871-4884, 2022 | 45 | 2022 |
| Quantification of global transcription patterns in prokaryotes using spotted microarrays B Sidders, M Withers, SL Kendall, J Bacon, SJ Waddell, J Hinds, P Golby, ... Genome Biology 8, 1-13, 2007 | 42 | 2007 |
Neil StokerUniversity College LondonE-mail megerősítve itt: ucl.ac.uk